Combination Of Lapatinib With Cetuximab To Overcome Resistance In EGFR-Driven Tumors: Study - Med India

Though targeted therapies have been studied for years recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy. This kind of ...

Merck KGaA's Erbitux Faces Hurdle - Analyst Blog - NASDAQ

Merck KGaA ( MKGAF) recently reported disappointing interim data from a late-stage study (PETACC-8) on Erbitux (cetuximab), which is being evaluated as an adjuvant treatment of stage III colon cancer. The data did not support the use of the drug ...

Head and neck cancer: Cetuximab in combination with Docetaxel and Cisplatin as induction therapy - Xagena Medical News

Patients treated for locally advanced head and neck cancer may respond better to treatment with the addition of Cetuximab ( Erbitux ) to chemotherapy, according to a phase II study. In the study, 39 patients with stages 3 or 4 head and neck cancer were ...

Merck KGaA Says PETACC-8 Study Of Erbitux Shows No Benefit At Interim Analysis - RTT News

The study investigated the potential clinical utility of Erbitux (cetuximab) for the adjuvant treatment of stage III colon cancer after complete surgical removal of the primary tumor. The pre-specified interim analysis of the study did not support benefit ...

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study - 7thspace.com

KRAS mutations negatively affect outcome after treatment with cetuximab in metastatic colorectal cancer (mCRC) patients. As only 20% of KRAS wild type (WT) patients respond to cetuximab it is possible that other mutations, constitutively activating the ...

Merck PETACC-8 Study of Erbitux as Adjuvant Treatment in Colon Cancer Shows no Benefit at Pre-specified Interim Analysis - Phramalive.com

The study investigated the potential clinical utility of Erbitux® (cetuximab) for the adjuvant treatment of stage III colon cancer after complete surgical removal of the primary tumor. The pre-specified interim analysis of the study did not support ...

Class Of Cancer Drugs Linked To Eye Infections, MHRA Warns - Newsinferno.com

Erbitux (cetuximab), Tarceva (erlotinib), Iressa (gefitinib) and Vectibix, are used to treat EGFR-expressing tumors. The cornea is covered with a layer of epithelium, which may become damaged when patients are receiving EGFR treatment.

Study combines lapatinib with cetuximab to overcome resistance in EGFR-driven tumors, new research suggests - Eureka! Science News

Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy. That kind of ...

Transgenomic Announces CE IVD Mark for the WAVE MCE System and SURVEYOR® Scan KRAS Kit in Europe - Genetic Engineering News

Mutations in the KRAS gene are key determinants of the effectiveness of modern cancer drugs such as Erbitux ® (cetuximab) and Vectibix ® (panitumumab), and detection of this mutation is important for the physicians’ decision-making regarding ...

Transgenomic Announces CE IVD Mark for the WAVE MCE System and SURVEYOR(R) Scan KRAS Kit in Europe - Marketwatch

Mutations in the KRAS gene are key determinants of the effectiveness of modern cancer drugs such as Erbitux(R) (cetuximab) and Vectibix(R) (panitumumab), and detection of this mutation is important for the physicians' decision-making regarding ...